Attention has turned to the regulatory path worldwide after Belite Bio Inc. unveiled positive top-line data from the phase III Dragon study with oral, daily tinlarebant in Stargardt disease type 1, ...

Proving its latest addition to the Farapulse pulsed field ablation (PFA) platform is no turkey, Boston Scientific Corp.'s Farapoint PFA catheter received CE mark as the U.S. celebrated Thanksgiving.

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...

HIV since at least the advent of antiretroviral therapy. In a report on “Overcoming disruption, transforming the AIDS response,” released last week ahead of World AIDS Day on Dec. 1, the Joint United ...

Ascletis Pharma Inc. has selected ASC-37 oral tablets as a clinical development candidate for the treatment of obesity. The company expects to submit an IND application to the FDA in the second ...

Q32 Bio Inc. handed off rights to phase II-stage complement inhibitor ADX-097 in a deal with Akebia Therapeutics Inc. that ...

Med-tech dealmaking totaled $1.72 billion through the first three quarters of 2025, signaling a potential rebound in the works from the subdued activity seen in 2024, when publicly reported full-year ...

New hires and promotions in the med-tech industry, including: Beyond Air, Hedia, Novocure, Ronovo Surgical. Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing ...

Biopharma happenings, including deals and partnerships, and other news in brief: Anges, Biosidus, Mural, Prestige, RK, Roche, Vasomune, Xoma, Zydus.

Protego Biopharma Inc. closed an oversubscribed $130 million series B financing that will be used to advance PROT-001, the company’s treatment for amyloid light (AL) chain amyloidosis. a plasma cell ...

The European Investment Bank and Angelini Ventures have partnered to invest €150 million (US$174 million) in health care companies across Europe. The funding will target seven to 10 companies in ...

The recommendation by a committee advising the U.K. government that screening for prostate cancer should not be made available to the vast majority of men could benefit companies such as Antegenes OÜ.